Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bioverativ Inc.
Double Blow For Sangamo’s Zinc Finger Approach As Novartis And Biogen Deals Collapse
The US biotech is facing yet another setback on its journey to proof-of-concept for its proprietary gene editing technology as two pharma firms back out of collaborations in the neurological space.
Star And Portfolio Firm Electra Roll Out With Focus On Rare Immunologic Disease
Star will employ a hub-and-spoke model to launch portfolio companies focused on specific biological areas. The first company, Electra, will emphasize unmet medical needs and therapies that can address multiple diseases.
Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
$1bn Amunix Buy Brings Sanofi Next-Generation TCE Platform
The deal bolsters Sanofi’s immuno-oncology pipeline and marks its sixth acquisition this year.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- True North Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.